Patrick M. Terheyden

Patrick M. Terheyden

Ratzeburger Allee 160
Luebeck, SH 23538, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 136 publications

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 16, 2026

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma.

Journal: Cancers

Published: January 13, 2026

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Journal: Journal for immunotherapy of cancer

Published: November 30, 2025

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 12, 2025

Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project.

Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE project.

Journal: Melanoma management

Published: August 29, 2025

Increased risk of deep vein thrombosis, pulmonary embolism, and all-cause mortality in chronic venous disorder: a large-scale retrospective cohort study.

Increased risk of deep vein thrombosis, pulmonary embolism, and all-cause mortality in chronic venous disorder: a large-scale retrospective cohort study.

Journal: Frontiers in medicine

Published: August 11, 2025

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Melanoma of unknown primary shows an oncogenic pattern and clinical course of sun-exposed melanoma.

Journal: The British journal of dermatology

Published: August 06, 2025

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Outcome of systemic therapy in patients with advanced rare skin cancers: A retrospective multicenter DeCOG study of 209 patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: August 03, 2025

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Real-world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study.

Journal: International journal of cancer

Published: May 23, 2025

Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG.

Sex-specific survival in advanced metastatic melanoma - a DeCOG study on 2032 patients of the multicenter prospective skin cancer registry ADOREG.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 18, 2025

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Real-world experience with first- versus second-line cemiplimab for advanced basal cell carcinoma.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 24, 2025

Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

Journal: ESMO open

Published: January 30, 2025

Showing 1-12 of 136

Last Updated: 09/26/2026